Results 1 to 10 of about 2,519,772 (150)

Obeticholic Acid for Primary Biliary Cholangitis [PDF]

Biomedicines, 2022
Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis and/or cirrhosis. Treatment options are currently limited.
Annarosa Floreani, Daniela Gabbia, Sara De Martin   +2 more
doaj   +4 more sources

Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Clin Pharmacol Ther
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Mayo AK, Beaudoin JJ, Woodhead JL, Watkins PB, Brouwer KLR.   +4 more
europepmc   +2 more sources

Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension. [PDF]

Aliment Pharmacol Ther
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Bowlus CL, Nevens F, Kowdley KV, Bonder A, Capozza T, Li J, Nair R, Trauner M, Jones DE.   +8 more
europepmc   +2 more sources

Obeticholic Acid and Edaravone Protect Against Cisplatin-Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF-α/NF-κB, and AKT/GSK-3β Pathways. [PDF]

J Biochem Mol Toxicol
The graphical abstract explores the possible underlying molecular mechanisms of Obeticholic acid against hepatotoxicity induced by chemotherapy exposure. ABSTRACT Hepatotoxicity is one of the most crucial side effects of chemotherapy administration. Obeticholic acid (OCA) is a semisynthetic bile acid and farnesoid X receptor (FXR) agonist derived from ...
Ali FEM, Bakr AG, Shalkami AS, El-Shoura EAM, Ahmed LK, Abd-Elsalam AF, Ahmed AAN, Hassanein EHM.   +7 more
europepmc   +2 more sources

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice [PDF]

Frontiers in Pharmacology, 2022
Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses.
Chuangzhen Lin, Bingqing Yu, Lixin Chen, Zhaohui Zhang, Weixiang Ye, Hui Zhong, Wenke Bai, Yuping Yang, Biao Nie   +8 more
doaj   +2 more sources

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. [PDF]

PLoS ONE, 2022
BackgroundSuppression of cardiac iinflammasome, which can be inhibited by Farnesoid X receptor (FXR) agonist, can ameliorate cardiac inflammation and fibrosis.
Szu-Yu Liu, Chia-Chang Huang, Ying-Ying Yang, Shiang-Fen Huang, Tzung-Yan Lee, Tzu-Hao Li, Ming-Chih Hou, Han-Chieh Lin   +7 more
doaj   +4 more sources

Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity [PDF]

Frontiers in Pharmacology
Background and aims:High-dose Obeticholic acid exhibits promise for non-alcoholic fatty liver disease (NAFLD) treatment but can induce lipotoxicity.
Yuping Yang, Yuping Yang, Weinan Yuan, Kun He, Chuangzhen Lin, Chuangzhen Lin, Shenshen Du, Yanqi Kou, Biao Nie   +8 more
doaj   +2 more sources

Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways [PDF]

BMC Pharmacology and Toxicology
Background The aim of the current study is to identify the possible protective effect of obeticholic acid (OCA) on placental injury caused by cyclophosphamide (CP). OCA was administered in the presence and absence of CP.
Walaa Yehia Abdelzaher, Hanaa Mohamed Khalaf, Sara M. Ahmed, Mina Ezzat Attya, Abdelaleem Abdelnour Mohamed, Asmaa Mohamed Mahmoud Ali, Shereen S. Gaber, Ahmed K. A. Abdel-Hakeem, Enas Mostafa Mohammed, Marwa Hassan   +9 more
doaj   +2 more sources

Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System [PDF]

Cells
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing health concern worldwide. Human cell-based in vitro culture models that retain disease-relevant phenotypic pathways and responses to assess the efficacy and liability of new ...
Justin J. Odanga, Sharon M. Anderson, Edward L. LeCluyse, Sharon C. Presnell, Jingsong Chen, Jessica R. Weaver   +5 more
doaj   +2 more sources

Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis [PDF]

Pharmaceuticals
Background/Objectives: Abnormal bile acid (BA) pool may play an important role in inducing liver damage in sepsis. Farnesoid X receptor (FXR) is a main negative feedback regulator of BA metabolism.
Jiahui Wang, Li Ma, Yuan An, Yan Ge, Dan Xu, Enqiang Mao   +5 more
doaj   +2 more sources